SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '4htz'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1BSX_A_T3A1_1 (PROTEIN (THYROID HORMONE RECEPTOR BETA))	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	ILE A 870 ALA A 767 LEU A 689 ILE A 764 PHE A 878	None	1.14A	1bsxA-4htzA: 1.9	1bsxA-4htzA: 24.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1BSX_B_T3B2_1 (PROTEIN (THYROID HORMONE RECEPTOR BETA))	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	ILE A 870 ALA A 767 LEU A 689 ILE A 764 PHE A 878	None	1.15A	1bsxB-4htzA: 1.8	1bsxB-4htzA: 24.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ERR_A_RALA600_2 (ESTROGEN RECEPTOR)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 6	LEU A 809 LEU A 802 HIS A 696 LEU A 677	None None ZN A1001 (-3.4A) None	0.88A	1errA-4htzA: undetectable	1errA-4htzA: 21.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 9	TYR A 655 LEU A 770 LEU A 809 GLN A 859 PHE A 862	None	0.53A	1tbfA-4htzA: 43.8	1tbfA-4htzA: 34.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UDU_A_CIAA1003_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 11	TYR A 655 ILE A 822 PHE A 830 ILE A 855 GLN A 859 PHE A 862	None	0.68A	1uduA-4htzA: 39.1	1uduA-4htzA: 35.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UDU_B_CIAB2003_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 ILE A 822 PHE A 830 GLN A 859 PHE A 862	None	0.68A	1uduB-4htzA: 39.1	1uduB-4htzA: 35.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UHO_A_VDNA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 10	TYR A 655 HIS A 656 PHE A 830 GLN A 859 PHE A 862	None	0.21A	1uhoA-4htzA: 40.8	1uhoA-4htzA: 35.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1X8V_A_ESLA472_1 (CYTOCHROME P450 51)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 6	MET A 694 LEU A 738 PHE A 746 MET A 761	None	1.13A	1x8vA-4htzA: undetectable	1x8vA-4htzA: 19.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XLX_A_CIOA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 12	TYR A 655 HIS A 656 HIS A 700 LEU A 809 ILE A 826 GLN A 859 PHE A 862	None	0.67A	1xlxA-4htzA: 38.7	1xlxA-4htzA: 27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 12	TYR A 655 HIS A 656 HIS A 700 ILE A 826 PHE A 830 GLN A 859 PHE A 862	None	0.42A	1xlxB-4htzA: 38.6	1xlxB-4htzA: 27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 ILE A 826 MET A 847 GLN A 859 PHE A 862	None	0.89A	1xlxB-4htzA: 38.6	1xlxB-4htzA: 27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XMU_A_ROFA101_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 12	TYR A 655 HIS A 656 ASP A 808 LEU A 809 ILE A 826 PHE A 830 PHE A 862	None None ZN A1001 (-2.5A) None None None None	0.64A	1xmuA-4htzA: 38.7	1xmuA-4htzA: 27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XMU_B_ROFB102_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 12	TYR A 655 HIS A 656 ASP A 808 LEU A 809 ILE A 826 PHE A 830	None None ZN A1001 (-2.5A) None None None	0.54A	1xmuB-4htzA: 38.8	1xmuB-4htzA: 27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 ASP A 697 ILE A 826 PHE A 830 MET A 847	None MG A1002 ( 2.6A) None None None	1.29A	1xomA-4htzA: 38.6	1xomA-4htzA: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	8 / 12	TYR A 655 ASP A 808 LEU A 809 ILE A 826 PHE A 830 MET A 847 GLN A 859 PHE A 862	None ZN A1001 (-2.5A) None None None None None None	0.97A	1xomA-4htzA: 38.6	1xomA-4htzA: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	8 / 12	TYR A 655 HIS A 656 ASP A 808 LEU A 809 ILE A 826 PHE A 830 GLN A 859 PHE A 862	None None ZN A1001 (-2.5A) None None None None None	0.67A	1xomA-4htzA: 38.6	1xomA-4htzA: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 12	TYR A 655 HIS A 656 LEU A 809 ILE A 826 PHE A 830 GLN A 859 PHE A 862	None	0.67A	1xomB-4htzA: 38.9	1xomB-4htzA: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 12	TYR A 655 LEU A 809 ILE A 826 PHE A 830 MET A 847 GLN A 859 PHE A 862	None	0.92A	1xomB-4htzA: 38.9	1xomB-4htzA: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOQ_A_ROFA502_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 12	TYR A 655 HIS A 656 ASP A 808 LEU A 809 ILE A 826 PHE A 862	None None ZN A1001 (-2.5A) None None None	0.64A	1xoqA-4htzA: 38.6	1xoqA-4htzA: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOQ_B_ROFB501_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 12	TYR A 655 HIS A 656 ASP A 808 LEU A 809 ILE A 826 PHE A 862	None None ZN A1001 (-2.5A) None None None	0.66A	1xoqB-4htzA: 38.8	1xoqB-4htzA: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOQ_B_ROFB501_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 LEU A 809 ILE A 826 MET A 847 PHE A 862	None	1.11A	1xoqB-4htzA: 38.8	1xoqB-4htzA: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 12	TYR A 655 ASP A 808 LEU A 809 MET A 847 GLN A 859 PHE A 862 ILE A 866	None ZN A1001 (-2.5A) None None None None None	0.90A	1xosA-4htzA: 38.8	1xosA-4htzA: 27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	8 / 12	TYR A 655 HIS A 656 ASP A 808 LEU A 809 PHE A 830 GLN A 859 PHE A 862 ILE A 866	None None ZN A1001 (-2.5A) None None None None None	0.60A	1xosA-4htzA: 38.8	1xosA-4htzA: 27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 HIS A 660 GLN A 859 PHE A 862 ILE A 866	None ZN A1001 (-3.4A) None None None	1.38A	1xosA-4htzA: 38.8	1xosA-4htzA: 27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOT_A_VDNA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 12	TYR A 655 HIS A 656 LEU A 809 ILE A 826 GLN A 859 PHE A 862 ILE A 866	None	0.50A	1xotA-4htzA: 38.8	1xotA-4htzA: 27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOT_A_VDNA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 12	TYR A 655 LEU A 809 ILE A 826 MET A 847 GLN A 859 PHE A 862 ILE A 866	None	0.82A	1xotA-4htzA: 38.8	1xotA-4htzA: 27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOT_B_VDNB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 12	TYR A 655 HIS A 656 LEU A 809 ILE A 826 MET A 847 GLN A 859 PHE A 862	None	0.76A	1xotB-4htzA: 38.9	1xotB-4htzA: 27.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOZ_A_CIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 ILE A 822 PHE A 830 ILE A 855 GLN A 859	None	0.73A	1xozA-4htzA: 43.9	1xozA-4htzA: 34.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOZ_A_CIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 PHE A 830 ILE A 855 GLN A 859 PHE A 862	None	0.40A	1xozA-4htzA: 43.9	1xozA-4htzA: 34.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2C8A_C_NCAC1252_0 (MONO-ADP-RIBOSYLTRAN SFERASE C3)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 6	ARG A 728 SER A 724 ARG A 762 GLU A 727	None	1.07A	2c8aC-4htzA: undetectable	2c8aC-4htzA: 20.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 11	TYR A 655 HIS A 656 PHE A 830 ILE A 855 GLN A 859 PHE A 862	None	0.45A	2h42A-4htzA: 40.3	2h42A-4htzA: 35.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_B_VIAB902_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 HIS A 656 ILE A 855 GLN A 859 PHE A 862	None	0.42A	2h42B-4htzA: 40.3	2h42B-4htzA: 35.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 12	TYR A 655 LEU A 770 LEU A 809 PHE A 830 ILE A 855 GLN A 859 PHE A 862	None	0.57A	2h42C-4htzA: 40.1	2h42C-4htzA: 35.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Q0I_A_BEZA990_0 (QUINOLONE SIGNAL RESPONSE PROTEIN)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 8	ASP A 808 ASP A 697 HIS A 660 SER A 665	ZN A1001 (-2.5A) MG A1002 ( 2.6A) ZN A1001 (-3.4A) None	1.09A	2q0iA-4htzA: undetectable	2q0iA-4htzA: 22.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Q0J_A_BEZA500_0 (QUINOLONE SIGNAL RESPONSE PROTEIN)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 10	ASP A 808 HIS A 656 ASP A 697 GLU A 727 LEU A 770	ZN A1001 (-2.5A) None MG A1002 ( 2.6A) None None	1.21A	2q0jA-4htzA: undetectable	2q0jA-4htzA: 21.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Q0J_B_BEZB500_0 (QUINOLONE SIGNAL RESPONSE PROTEIN)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 11	ASP A 808 HIS A 656 ASP A 697 GLU A 727 LEU A 770	ZN A1001 (-2.5A) None MG A1002 ( 2.6A) None None	1.23A	2q0jB-4htzA: undetectable	2q0jB-4htzA: 21.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WEY_A_EV1A1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	11 / 12	TYR A 655 HIS A 656 LEU A 770 LEU A 809 ILE A 826 TYR A 827 GLU A 829 PHE A 830 MET A 847 GLN A 859 PHE A 862	None	0.65A	2weyA-4htzA: 41.2	2weyA-4htzA: 35.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WEY_B_EV1B1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 8	LEU A 623 VAL A 646 PHE A 746 MET A 757	None	0.89A	2weyB-4htzA: 40.9	2weyB-4htzA: 35.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WEY_B_EV1B1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 8	LEU A 770 ILE A 826 TYR A 827 PHE A 830 MET A 847 GLN A 859 PHE A 862	None	0.68A	2weyB-4htzA: 40.9	2weyB-4htzA: 35.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3B2R_A_VDNA1_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 12	TYR A 655 HIS A 656 LEU A 809 PHE A 830 ILE A 855 GLN A 859 PHE A 862	None	0.61A	3b2rA-4htzA: 35.8	3b2rA-4htzA: 35.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3B2R_B_VDNB1_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 11	TYR A 655 HIS A 656 LEU A 809 ILE A 855 GLN A 859 PHE A 862	None	0.61A	3b2rB-4htzA: 35.7	3b2rB-4htzA: 35.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_A_ROFA901_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	3 / 3	ASP A 808 LEU A 809 GLN A 859	ZN A1001 (-2.5A) None None	0.45A	3g4lA-4htzA: 38.5	3g4lA-4htzA: 27.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_B_ROFB902_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 12	TYR A 655 HIS A 656 ASP A 808 LEU A 809 ILE A 826 PHE A 862	None None ZN A1001 (-2.5A) None None None	0.58A	3g4lB-4htzA: 38.6	3g4lB-4htzA: 27.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_B_ROFB902_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 LEU A 809 ILE A 826 MET A 847 PHE A 862	None	0.99A	3g4lB-4htzA: 38.6	3g4lB-4htzA: 27.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_C_ROFC903_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	TYR A 655 HIS A 656 ASP A 808 LEU A 809 ILE A 826	None None ZN A1001 (-2.5A) None None	0.52A	3g4lC-4htzA: 38.5	3g4lC-4htzA: 27.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_D_ROFD904_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 12	TYR A 655 HIS A 656 ASP A 808 LEU A 809 ILE A 826 GLN A 859	None None ZN A1001 (-2.5A) None None None	0.60A	3g4lD-4htzA: 38.8	3g4lD-4htzA: 27.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3GLQ_B_RABB602_2 (ADENOSYLHOMOCYSTEINA SE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 5	GLN A 708 GLU A 727 THR A 768 HIS A 696	None None MG A1002 ( 4.7A) ZN A1001 (-3.4A)	1.38A	3glqB-4htzA: undetectable	3glqB-4htzA: 21.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 9	TYR A 655 ILE A 826 PHE A 830 GLN A 859 PHE A 862 ILE A 866	None	0.43A	3iakA-4htzA: 38.1	3iakA-4htzA: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 9	TYR A 655 ILE A 826 PHE A 830 MET A 847 PHE A 862 ILE A 866	None	0.85A	3iakA-4htzA: 38.1	3iakA-4htzA: 28.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 9	TYR A 655 HIS A 656 LEU A 770 MET A 847 GLN A 859 PHE A 862	None	0.39A	3jwqA-4htzA: 44.3	3jwqA-4htzA: 35.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 11	TYR A 655 HIS A 656 ASN A 704 LEU A 770 MET A 847 GLN A 859 PHE A 862	None	0.80A	3jwqB-4htzA: 44.1 3jwqC-4htzA: 44.2	3jwqB-4htzA: 35.54 3jwqC-4htzA: 35.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 7	TYR A 655 HIS A 656 MET A 847 GLN A 859 PHE A 862	None	0.42A	3jwqC-4htzA: 44.2	3jwqC-4htzA: 35.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	7 / 11	TYR A 655 HIS A 656 LEU A 770 PHE A 830 MET A 847 GLN A 859 PHE A 862	None	0.66A	3jwqA-4htzA: 44.3 3jwqD-4htzA: 43.9	3jwqA-4htzA: 35.54 3jwqD-4htzA: 35.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 11	TYR A 655 HIS A 656 LEU A 770 PHE A 830 MET A 848	None	1.28A	3jwqA-4htzA: 44.3 3jwqD-4htzA: 43.9	3jwqA-4htzA: 35.54 3jwqD-4htzA: 35.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3KP6_B_SALB3001_1 (TRANSCRIPTIONAL REGULATOR TCAR)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 8	GLU A 893 ASN A 891 MET A 863 ILE A 860	None	1.16A	3kp6A-4htzA: undetectable 3kp6B-4htzA: undetectable	3kp6A-4htzA: 19.71 3kp6B-4htzA: 19.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3N58_A_ADNA500_2 (ADENOSYLHOMOCYSTEINA SE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 5	GLN A 708 GLU A 727 THR A 768 HIS A 696	None None MG A1002 ( 4.7A) ZN A1001 (-3.4A)	1.32A	3n58A-4htzA: undetectable	3n58A-4htzA: 20.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3TVX_A_PNXA902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 9	TYR A 655 LEU A 809 ILE A 826 GLN A 859 PHE A 862	None	0.54A	3tvxA-4htzA: 39.0	3tvxA-4htzA: 28.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3TVX_A_PNXA902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 9	TYR A 655 LEU A 809 ILE A 826 MET A 847 PHE A 862	None	0.91A	3tvxA-4htzA: 39.0	3tvxA-4htzA: 28.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3TVX_B_PNXB902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	6 / 7	TYR A 655 ILE A 826 PHE A 830 MET A 847 GLN A 859 PHE A 862	None	0.82A	3tvxB-4htzA: 38.9	3tvxB-4htzA: 28.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4LVC_A_ADNA501_2 (S-ADENOSYL-L-HOMOCYS TEINE HYDROLASE (SAHASE))	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 5	GLN A 875 THR A 805 HIS A 773 LEU A 780	None	1.25A	4lvcA-4htzA: undetectable	4lvcA-4htzA: 19.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4LVC_C_ADNC501_2 (S-ADENOSYL-L-HOMOCYS TEINE HYDROLASE (SAHASE))	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 5	GLN A 875 THR A 805 HIS A 773 LEU A 780	None	1.26A	4lvcC-4htzA: undetectable	4lvcC-4htzA: 19.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4N09_A_ADNA401_2 (ADENOSINE KINASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 4	LEU A 884 SER A 810 LEU A 670 LEU A 874	None	1.06A	4n09A-4htzA: undetectable	4n09A-4htzA: 20.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RP8_C_ASCC501_0 (ASCORBATE-SPECIFIC PERMEASE IIC COMPONENT ULAA)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 12	LEU A 639 ILE A 619 ILE A 634 ILE A 691 PHE A 687	None	1.05A	4rp8C-4htzA: 2.1	4rp8C-4htzA: 20.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HW8_D_FK5D201_1 (FK506-BINDING PROTEIN 1)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 11	TYR A 669 ASP A 625 PHE A 600 ILE A 619 ILE A 629	None	1.23A	5hw8D-4htzA: undetectable	5hw8D-4htzA: 16.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HW8_G_FK5G201_2 (FK506-BINDING PROTEIN 1)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	5 / 11	TYR A 669 ASP A 625 PHE A 600 ILE A 619 ILE A 590	None	1.19A	5hw8G-4htzA: undetectable	5hw8G-4htzA: 16.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OEX_A_CUA604_0 (THIOCYANATE DEHYDROGENASE)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	3 / 3	HIS A 660 HIS A 656 HIS A 700	ZN A1001 (-3.4A) None None	1.02A	5oexA-4htzA: undetectable	5oexA-4htzA: 20.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6GBN_A_ADNA501_2 (-)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 5	GLN A 875 THR A 805 HIS A 773 LEU A 780	None	1.28A	6gbnA-4htzA: undetectable	6gbnA-4htzA: 20.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6GBN_D_ADND501_2 (-)	4htz	CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE (Homo sapiens)	4 / 5	GLN A 875 THR A 805 HIS A 773 LEU A 780	None	1.29A	6gbnD-4htzA: undetectable	6gbnD-4htzA: 20.83

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1BSX_A_T3A1_1","PROTEIN (THYROID HORMONE RECEPTOR BETA)","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"ILE A 870;ALA A 767;LEU A 689;ILE A 764;PHE A 878","None","1.14A","1bsxA-4htzA:1.9","1bsxA-4htzA:24.29"],["1BSX_B_T3B2_1","PROTEIN (THYROID HORMONE RECEPTOR BETA)","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"ILE A 870;ALA A 767;LEU A 689;ILE A 764;PHE A 878","None","1.15A","1bsxB-4htzA:1.8","1bsxB-4htzA:24.29"],["1ERR_A_RALA600_2","ESTROGEN RECEPTOR","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"LEU A 809;LEU A 802;HIS A 696;LEU A 677","None;None; ZN A1001 (-3.4A);None","0.88A","1errA-4htzA:undetectable","1errA-4htzA:21.53"],["1TBF_A_VIAA501_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;LEU A 770;LEU A 809;GLN A 859;PHE A 862","None","0.53A","1tbfA-4htzA:43.8","1tbfA-4htzA:34.39"],["1UDU_A_CIAA1003_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 655;ILE A 822;PHE A 830;ILE A 855;GLN A 859;PHE A 862","None","0.68A","1uduA-4htzA:39.1","1uduA-4htzA:35.75"],["1UDU_B_CIAB2003_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;ILE A 822;PHE A 830;GLN A 859;PHE A 862","None","0.68A","1uduB-4htzA:39.1","1uduB-4htzA:35.75"],["1UHO_A_VDNA1000_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;HIS A 656;PHE A 830;GLN A 859;PHE A 862","None","0.21A","1uhoA-4htzA:40.8","1uhoA-4htzA:35.75"],["1X8V_A_ESLA472_1","CYTOCHROME P450 51","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"MET A 694;LEU A 738;PHE A 746;MET A 761","None","1.13A","1x8vA-4htzA:undetectable","1x8vA-4htzA:19.80"],["1XLX_A_CIOA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 655;HIS A 656;HIS A 700;LEU A 809;ILE A 826;GLN A 859;PHE A 862","None","0.67A","1xlxA-4htzA:38.7","1xlxA-4htzA:27.55"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 655;HIS A 656;HIS A 700;ILE A 826;PHE A 830;GLN A 859;PHE A 862","None","0.42A","1xlxB-4htzA:38.6","1xlxB-4htzA:27.55"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;ILE A 826;MET A 847;GLN A 859;PHE A 862","None","0.89A","1xlxB-4htzA:38.6","1xlxB-4htzA:27.55"],["1XMU_A_ROFA101_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 655;HIS A 656;ASP A 808;LEU A 809;ILE A 826;PHE A 830;PHE A 862","None;None; ZN A1001 (-2.5A);None;None;None;None","0.64A","1xmuA-4htzA:38.7","1xmuA-4htzA:27.55"],["1XMU_B_ROFB102_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 655;HIS A 656;ASP A 808;LEU A 809;ILE A 826;PHE A 830","None;None; ZN A1001 (-2.5A);None;None;None","0.54A","1xmuB-4htzA:38.8","1xmuB-4htzA:27.55"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;ASP A 697;ILE A 826;PHE A 830;MET A 847","None; MG A1002 ( 2.6A);None;None;None","1.29A","1xomA-4htzA:38.6","1xomA-4htzA:28.53"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",8,"TYR A 655;ASP A 808;LEU A 809;ILE A 826;PHE A 830;MET A 847;GLN A 859;PHE A 862","None; ZN A1001 (-2.5A);None;None;None;None;None;None","0.97A","1xomA-4htzA:38.6","1xomA-4htzA:28.53"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",8,"TYR A 655;HIS A 656;ASP A 808;LEU A 809;ILE A 826;PHE A 830;GLN A 859;PHE A 862","None;None; ZN A1001 (-2.5A);None;None;None;None;None","0.67A","1xomA-4htzA:38.6","1xomA-4htzA:28.53"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 655;HIS A 656;LEU A 809;ILE A 826;PHE A 830;GLN A 859;PHE A 862","None","0.67A","1xomB-4htzA:38.9","1xomB-4htzA:28.53"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 655;LEU A 809;ILE A 826;PHE A 830;MET A 847;GLN A 859;PHE A 862","None","0.92A","1xomB-4htzA:38.9","1xomB-4htzA:28.53"],["1XOQ_A_ROFA502_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 655;HIS A 656;ASP A 808;LEU A 809;ILE A 826;PHE A 862","None;None; ZN A1001 (-2.5A);None;None;None","0.64A","1xoqA-4htzA:38.6","1xoqA-4htzA:28.53"],["1XOQ_B_ROFB501_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 655;HIS A 656;ASP A 808;LEU A 809;ILE A 826;PHE A 862","None;None; ZN A1001 (-2.5A);None;None;None","0.66A","1xoqB-4htzA:38.8","1xoqB-4htzA:28.53"],["1XOQ_B_ROFB501_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;LEU A 809;ILE A 826;MET A 847;PHE A 862","None","1.11A","1xoqB-4htzA:38.8","1xoqB-4htzA:28.53"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 655;ASP A 808;LEU A 809;MET A 847;GLN A 859;PHE A 862;ILE A 866","None; ZN A1001 (-2.5A);None;None;None;None;None","0.90A","1xosA-4htzA:38.8","1xosA-4htzA:27.55"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",8,"TYR A 655;HIS A 656;ASP A 808;LEU A 809;PHE A 830;GLN A 859;PHE A 862;ILE A 866","None;None; ZN A1001 (-2.5A);None;None;None;None;None","0.60A","1xosA-4htzA:38.8","1xosA-4htzA:27.55"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;HIS A 660;GLN A 859;PHE A 862;ILE A 866","None; ZN A1001 (-3.4A);None;None;None","1.38A","1xosA-4htzA:38.8","1xosA-4htzA:27.55"],["1XOT_A_VDNA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 655;HIS A 656;LEU A 809;ILE A 826;GLN A 859;PHE A 862;ILE A 866","None","0.50A","1xotA-4htzA:38.8","1xotA-4htzA:27.55"],["1XOT_A_VDNA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 655;LEU A 809;ILE A 826;MET A 847;GLN A 859;PHE A 862;ILE A 866","None","0.82A","1xotA-4htzA:38.8","1xotA-4htzA:27.55"],["1XOT_B_VDNB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 655;HIS A 656;LEU A 809;ILE A 826;MET A 847;GLN A 859;PHE A 862","None","0.76A","1xotB-4htzA:38.9","1xotB-4htzA:27.55"],["1XOZ_A_CIAA501_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;ILE A 822;PHE A 830;ILE A 855;GLN A 859","None","0.73A","1xozA-4htzA:43.9","1xozA-4htzA:34.30"],["1XOZ_A_CIAA501_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;PHE A 830;ILE A 855;GLN A 859;PHE A 862","None","0.40A","1xozA-4htzA:43.9","1xozA-4htzA:34.30"],["2C8A_C_NCAC1252_0","MONO-ADP-RIBOSYLTRANSFERASE C3","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"ARG A 728;SER A 724;ARG A 762;GLU A 727","None","1.07A","2c8aC-4htzA:undetectable","2c8aC-4htzA:20.35"],["2H42_A_VIAA901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 655;HIS A 656;PHE A 830;ILE A 855;GLN A 859;PHE A 862","None","0.45A","2h42A-4htzA:40.3","2h42A-4htzA:35.83"],["2H42_B_VIAB902_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;HIS A 656;ILE A 855;GLN A 859;PHE A 862","None","0.42A","2h42B-4htzA:40.3","2h42B-4htzA:35.83"],["2H42_C_VIAC903_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 655;LEU A 770;LEU A 809;PHE A 830;ILE A 855;GLN A 859;PHE A 862","None","0.57A","2h42C-4htzA:40.1","2h42C-4htzA:35.83"],["2Q0I_A_BEZA990_0","QUINOLONE SIGNAL RESPONSE PROTEIN","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"ASP A 808;ASP A 697;HIS A 660;SER A 665"," ZN A1001 (-2.5A); MG A1002 ( 2.6A); ZN A1001 (-3.4A);None","1.09A","2q0iA-4htzA:undetectable","2q0iA-4htzA:22.13"],["2Q0J_A_BEZA500_0","QUINOLONE SIGNAL RESPONSE PROTEIN","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"ASP A 808;HIS A 656;ASP A 697;GLU A 727;LEU A 770"," ZN A1001 (-2.5A);None; MG A1002 ( 2.6A);None;None","1.21A","2q0jA-4htzA:undetectable","2q0jA-4htzA:21.20"],["2Q0J_B_BEZB500_0","QUINOLONE SIGNAL RESPONSE PROTEIN","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"ASP A 808;HIS A 656;ASP A 697;GLU A 727;LEU A 770"," ZN A1001 (-2.5A);None; MG A1002 ( 2.6A);None;None","1.23A","2q0jB-4htzA:undetectable","2q0jB-4htzA:21.20"],["2WEY_A_EV1A1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",11,"TYR A 655;HIS A 656;LEU A 770;LEU A 809;ILE A 826;TYR A 827;GLU A 829;PHE A 830;MET A 847;GLN A 859;PHE A 862","None","0.65A","2weyA-4htzA:41.2","2weyA-4htzA:35.26"],["2WEY_B_EV1B1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"LEU A 623;VAL A 646;PHE A 746;MET A 757","None","0.89A","2weyB-4htzA:40.9","2weyB-4htzA:35.26"],["2WEY_B_EV1B1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"LEU A 770;ILE A 826;TYR A 827;PHE A 830;MET A 847;GLN A 859;PHE A 862","None","0.68A","2weyB-4htzA:40.9","2weyB-4htzA:35.26"],["3B2R_A_VDNA1_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 655;HIS A 656;LEU A 809;PHE A 830;ILE A 855;GLN A 859;PHE A 862","None","0.61A","3b2rA-4htzA:35.8","3b2rA-4htzA:35.81"],["3B2R_B_VDNB1_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 655;HIS A 656;LEU A 809;ILE A 855;GLN A 859;PHE A 862","None","0.61A","3b2rB-4htzA:35.7","3b2rB-4htzA:35.81"],["3G4L_A_ROFA901_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",3,"ASP A 808;LEU A 809;GLN A 859"," ZN A1001 (-2.5A);None;None","0.45A","3g4lA-4htzA:38.5","3g4lA-4htzA:27.97"],["3G4L_B_ROFB902_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 655;HIS A 656;ASP A 808;LEU A 809;ILE A 826;PHE A 862","None;None; ZN A1001 (-2.5A);None;None;None","0.58A","3g4lB-4htzA:38.6","3g4lB-4htzA:27.97"],["3G4L_B_ROFB902_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;LEU A 809;ILE A 826;MET A 847;PHE A 862","None","0.99A","3g4lB-4htzA:38.6","3g4lB-4htzA:27.97"],["3G4L_C_ROFC903_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;HIS A 656;ASP A 808;LEU A 809;ILE A 826","None;None; ZN A1001 (-2.5A);None;None","0.52A","3g4lC-4htzA:38.5","3g4lC-4htzA:27.97"],["3G4L_D_ROFD904_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 655;HIS A 656;ASP A 808;LEU A 809;ILE A 826;GLN A 859","None;None; ZN A1001 (-2.5A);None;None;None","0.60A","3g4lD-4htzA:38.8","3g4lD-4htzA:27.97"],["3GLQ_B_RABB602_2","ADENOSYLHOMOCYSTEINASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"GLN A 708;GLU A 727;THR A 768;HIS A 696","None;None; MG A1002 ( 4.7A); ZN A1001 (-3.4A)","1.38A","3glqB-4htzA:undetectable","3glqB-4htzA:21.33"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 655;ILE A 826;PHE A 830;GLN A 859;PHE A 862;ILE A 866","None","0.43A","3iakA-4htzA:38.1","3iakA-4htzA:28.53"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 655;ILE A 826;PHE A 830;MET A 847;PHE A 862;ILE A 866","None","0.85A","3iakA-4htzA:38.1","3iakA-4htzA:28.53"],["3JWQ_A_VIAA901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 655;HIS A 656;LEU A 770;MET A 847;GLN A 859;PHE A 862","None","0.39A","3jwqA-4htzA:44.3","3jwqA-4htzA:35.54"],["3JWQ_B_VIAB901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA;CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 655;HIS A 656;ASN A 704;LEU A 770;MET A 847;GLN A 859;PHE A 862","None","0.80A","3jwqB-4htzA:44.1;3jwqC-4htzA:44.2","3jwqB-4htzA:35.54;3jwqC-4htzA:35.54"],["3JWQ_C_VIAC901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;HIS A 656;MET A 847;GLN A 859;PHE A 862","None","0.42A","3jwqC-4htzA:44.2","3jwqC-4htzA:35.54"],["3JWQ_D_VIAD901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA;CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",7,"TYR A 655;HIS A 656;LEU A 770;PHE A 830;MET A 847;GLN A 859;PHE A 862","None","0.66A","3jwqA-4htzA:44.3;3jwqD-4htzA:43.9","3jwqA-4htzA:35.54;3jwqD-4htzA:35.54"],["3JWQ_D_VIAD901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA;CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;HIS A 656;LEU A 770;PHE A 830;MET A 848","None","1.28A","3jwqA-4htzA:44.3;3jwqD-4htzA:43.9","3jwqA-4htzA:35.54;3jwqD-4htzA:35.54"],["3KP6_B_SALB3001_1","TRANSCRIPTIONAL REGULATOR TCAR;TRANSCRIPTIONAL REGULATOR TCAR","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"GLU A 893;ASN A 891;MET A 863;ILE A 860","None","1.16A","3kp6A-4htzA:undetectable;3kp6B-4htzA:undetectable","3kp6A-4htzA:19.71;3kp6B-4htzA:19.71"],["3N58_A_ADNA500_2","ADENOSYLHOMOCYSTEINASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"GLN A 708;GLU A 727;THR A 768;HIS A 696","None;None; MG A1002 ( 4.7A); ZN A1001 (-3.4A)","1.32A","3n58A-4htzA:undetectable","3n58A-4htzA:20.87"],["3TVX_A_PNXA902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;LEU A 809;ILE A 826;GLN A 859;PHE A 862","None","0.54A","3tvxA-4htzA:39.0","3tvxA-4htzA:28.98"],["3TVX_A_PNXA902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 655;LEU A 809;ILE A 826;MET A 847;PHE A 862","None","0.91A","3tvxA-4htzA:39.0","3tvxA-4htzA:28.98"],["3TVX_B_PNXB902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",6,"TYR A 655;ILE A 826;PHE A 830;MET A 847;GLN A 859;PHE A 862","None","0.82A","3tvxB-4htzA:38.9","3tvxB-4htzA:28.98"],["4LVC_A_ADNA501_2","S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE (SAHASE)","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"GLN A 875;THR A 805;HIS A 773;LEU A 780","None","1.25A","4lvcA-4htzA:undetectable","4lvcA-4htzA:19.92"],["4LVC_C_ADNC501_2","S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE (SAHASE)","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"GLN A 875;THR A 805;HIS A 773;LEU A 780","None","1.26A","4lvcC-4htzA:undetectable","4lvcC-4htzA:19.92"],["4N09_A_ADNA401_2","ADENOSINE KINASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"LEU A 884;SER A 810;LEU A 670;LEU A 874","None","1.06A","4n09A-4htzA:undetectable","4n09A-4htzA:20.32"],["4RP8_C_ASCC501_0","ASCORBATE-SPECIFIC PERMEASE IIC COMPONENT ULAA","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"LEU A 639;ILE A 619;ILE A 634;ILE A 691;PHE A 687","None","1.05A","4rp8C-4htzA:2.1","4rp8C-4htzA:20.25"],["5HW8_D_FK5D201_1","FK506-BINDING PROTEIN 1","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 669;ASP A 625;PHE A 600;ILE A 619;ILE A 629","None","1.23A","5hw8D-4htzA:undetectable","5hw8D-4htzA:16.72"],["5HW8_G_FK5G201_2","FK506-BINDING PROTEIN 1","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",5,"TYR A 669;ASP A 625;PHE A 600;ILE A 619;ILE A 590","None","1.19A","5hw8G-4htzA:undetectable","5hw8G-4htzA:16.72"],["5OEX_A_CUA604_0","THIOCYANATE DEHYDROGENASE","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",3,"HIS A 660;HIS A 656;HIS A 700"," ZN A1001 (-3.4A);None;None","1.02A","5oexA-4htzA:undetectable","5oexA-4htzA:20.13"],["6GBN_A_ADNA501_2","-","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"GLN A 875;THR A 805;HIS A 773;LEU A 780","None","1.28A","6gbnA-4htzA:undetectable","6gbnA-4htzA:20.83"],["6GBN_D_ADND501_2","-","4htz","CGMP-DEPENDENT 3',5'-CYCLIC PHOSPHODIESTERASE","Homo sapiens",4,"GLN A 875;THR A 805;HIS A 773;LEU A 780","None","1.29A","6gbnD-4htzA:undetectable","6gbnD-4htzA:20.83"]]